A Phase 3 interventional study of GFF MDI and GP MDI in Chronic Obstructive Pulmonary Disease, sponsored by Pearl Therapeutics, Inc.. Completed at 140 sites in 3 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-28.
Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca — 14 open to participants now, 15 under way, 4 of them phase 3. Pulmonary Disease, Chronic Obstructive · AstraZeneca.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 8th largest by enrollment of the 194 interventional ones that give a count, is one of 14 that started in 2013, is one of 76 in phase 3, and was the 133rd registered.
5,526 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →14 of the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
AstraZeneca · Sites in France
Ages 18–99
AstraZeneca · Sites in India
Ages 18+
AstraZeneca · Sites in Argentina, Egypt, Mexico and 4 more countries
Ages 18+
AstraZeneca · Sites in Argentina, Colombia, Egypt and 9 more countries
Ages 30–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
284 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 44 · Phase 2 57 · Phase 3 77 · Phase 4 19
First in 1999; this study’s year is marked. 14 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,103 is above the median of 62 across 3,844 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 137 across the 194 interventional studies, 976 across the 89 observational. Of the 264 that completed or were terminated, 127 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Pearl Therapeutics, Inc., one of the names counted as AstraZeneca. Under that name alone:
Pearl Therapeutics, Inc. is the lead sponsor of 42 studies on the registry; none are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 15 (94%) have results posted.
9 of the studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06712563AstraZenecaPooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting | 2026-12-14 |
| NCT07245576AstraZenecaAssess Accuracy of Primary Care Asthma and COPD Diagnosis Using Oscillometry and FeNO vs Specialist Diagnosis | 2027-04-30 |
| NCT07315958AstraZenecaStudy for Assessing the Prevalence of Airflow Limitation in Outpatients With History of Smoking Attending Cardiology Clinics | 2027-04-30 |
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
| NCT07307781AstraZenecaStudy of Patient With Frequent Exacerbations in Moscow | 2027-06-25 |
Add all 9 to your calendar (.ics) → With an account.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The overall objective of this study is to assess the efficacy and safety of treatment with PT003 (GFF MDI), PT005 (FF MDI), PT001 (GP MDI), and open-label tiotropium bromide inhalation powder compared with each other and Placebo MDI over 24 weeks in subjects with moderate to very severe COPD.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Glycopyrronium Formoterol Fumarate (GFF) Metered Dose Inhaler (MDI) (PT003)
Drug: GFF MDI
Glycopyrronium (GP) MDI (PT001)
Drug: GP MDI
Formoterol Fumarate (FF) MDI (PT005)
Drug: FF MDI
Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
Drug: Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)
Placebo MDI
Drug: Placebo MDI
GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
GP MDI administered as two puffs BID
FF MDI administered as two puffs BID
Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
Inhaled placebo administered as two puffs BID
Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24
Time frame: Baseline and at Week 24
Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.
Time frame: Baseline and Weeks 2 to 24
St. George's Respiratory Questionnaire (SGRQ) Score
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.
Time frame: Baseline and at Week 24
Rescue Ventolin Hydrofluoroalkane (HFA) Use
Change from baseline in average daily rescue Ventolin HFA use
Time frame: Baseline and at Week 24
Onset of Action as Assessed by FEV1
Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant
Time frame: Assessed for 5- and 15-minute post dose on Day 1
Peak Change From Baseline in FEV1 Within 2 Hours Post-dose
Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose
Time frame: Baseline and at Week 24
Conducted at 160 sites throughout the US, Australia, and New Zealand from June 2013 - February 2015. Study participation was a maximum of 32 weeks.
| Milestone | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| Started | 527 | 451 | 452 | 453 | 220 |
| Completed | 429 | 345 | 370 | 391 | 160 |
| Not completed | 98 | 106 | 82 | 62 | 60 |
| Withdrew: Protocol-specified criteria | 13 | 10 | 8 | 5 | 7 |
| Withdrew: Administrative reasons / missing | 0 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 3 | 0 | 5 | 4 | 1 |
| Withdrew: Lost to follow-up | 10 | 7 | 8 | 5 | 0 |
| Withdrew: Physician decision | 1 | 5 | 3 | 3 | 7 |
| Withdrew: Withdrawal by subject | 31 | 41 | 30 | 21 | 24 |
| Withdrew: Lack of efficacy | 7 | 12 | 9 | 3 | 9 |
| Withdrew: Adverse event | 33 | 31 | 19 | 20 | 11 |
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) at Week 24
| Liters | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 | 0.126 (0.107 to 0.145) | 0.066 (0.045 to 0.087) | 0.062 (0.041 to 0.082) | 0.105 (0.084 to 0.125) | -0.024 (-0.055 to 0.007) |
Change from baseline in morning pre-dose trough forced expiratory volume in 1 second (FEV1) over 24 weeks. FEV1 was assessed at multiple time points post-baseline,and a modelbased average of all visits starting from Week 2 through week 24 inclusive was calculated. The change values reported in the table represent the change between the baseline and the average FEV1 post-baseline.
| Liters | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks | 0.150 (0.136 to 0.164) | 0.091 (0.076 to 0.106) | 0.086 (0.071 to 0.101) | 0.122 (0.107 to 0.137) | -0.007 (-0.029 to 0.015) |
Change from baseline in the SGRQ total score. The SGRQ is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of GFF MDI, FF MDI and GP MDI on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.
| Scores on a scale | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| St. George's Respiratory Questionnaire (SGRQ) Score | -3.1 (-4.0 to -2.2) | -1.2 (-2.2 to -0.2) | -2.4 (-3.4 to -1.4) | -2.7 (-3.6 to -1.7) | -0.8 (-2.2 to 0.7) |
Change from baseline in average daily rescue Ventolin HFA use
| Puffs / Day | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| Rescue Ventolin Hydrofluoroalkane (HFA) Use | -0.8 (-1.0 to -0.6) | -0.5 (-0.7 to -0.3) | -0.8 (-1.0 to -0.6) | -0.4 (-0.6 to -0.2) | 0.3 (0.0 to 0.6) |
Defined as the first time-point using the 5- and 15-minute post dose measurements where the difference in FEV1 from Placebo was statistically significant
| Liters | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| 5 min post dose | 0.185 (0.175 to 0.195) | 0.042 (0.031 to 0.053) | 0.182 (0.171 to 0.193) | 0.048 (0.037 to 0.059) | -0.002 (-0.017 to 0.014) |
| 15 min post dose | 0.226 (0.216 to 0.237) | 0.101 (0.090 to 0.113) | 0.212 (0.201 to 0.224) | 0.117 (0.105 to 0.129) | 0.022 (0.005 to 0.038) |
Peak change from baseline in forced expiratory volume in 1 second (FEV1) within 2 hours post-dose
| Liters | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| Peak Change From Baseline in FEV1 Within 2 Hours Post-dose | 0.356 (0.335 to 0.377) | 0.223 (0.200 to 0.246) | 0.263 (0.240 to 0.285) | 0.259 (0.237 to 0.281) | 0.065 (0.031 to 0.098) |
Collected over SAEs and AEs were collected throughout study participation and for two weeks after study completion.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GFF MDI (PT003) | — | 44/526 (8.4%) | 73/526 (13.9%) |
| GP MDI (PT001) | — | 36/451 (8%) | 59/451 (13.1%) |
| FF MDI (PT005) | — | 29/452 (6.4%) | 57/452 (12.6%) |
| Spiriva® Handihaler® (Open-label) | — | 36/451 (8%) | 58/451 (12.9%) |
| Placebo | — | 16/220 (7.3%) | 47/220 (21.4%) |
| Event | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 15/526 | 17/451 | 8/452 | 8/451 | 7/220 |
| PneumoniaInfections and infestations | 8/526 | 7/451 | 0/452 | 1/451 | 1/220 |
| Chest painGeneral disorders | 1/526 | 2/451 | 1/452 | 0/451 | 2/220 |
| Squamous cell carcinoma of lungNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/526 | 0/451 | 0/452 | 3/451 | 0/220 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/526 | 0/451 | 0/452 | 0/451 | 1/220 |
| EpistatxisRespiratory, thoracic and mediastinal disorders | 0/526 | 0/451 | 0/452 | 0/451 | 1/220 |
| CellulitisInfections and infestations | 1/526 | 0/451 | 0/452 | 2/451 | 1/220 |
| PyelonephritisInfections and infestations | 0/526 | 0/451 | 0/452 | 0/451 | 1/220 |
| Coronary artery diseaseCardiac disorders | 1/526 | 1/451 | 0/452 | 1/451 | 1/220 |
| Acute myocardial infarctionCardiac disorders | 1/526 | 1/451 | 0/452 | 0/451 | 1/220 |
| Event | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo |
|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 43/526 | 23/451 | 28/452 | 26/451 | 18/220 |
| Upper respiratory tract infectionInfections and infestations | 17/526 | 20/451 | 14/452 | 17/451 | 16/220 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 13/526 | 16/451 | 15/452 | 15/451 | 13/220 |
7 subjects were excluded from analysis.
| Age, Continuous(Years) | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo | Total |
|---|---|---|---|---|---|---|
| Mean | 62.6 ± 8.4 | 62.9 ± 8.4 | 63.0 ± 8.3 | 63.0 ± 8.6 | 62.5 ± 8.3 | 62.8 ± 8.4 |
| Sex: Female, Male(Participants) | GFF MDI (PT003) | GP MDI (PT001) | FF MDI (PT005) | Spiriva® Handihaler® (Open-label) | Placebo | Total |
|---|---|---|---|---|---|---|
| Female | 236 | 196 | 203 | 182 | 97 | 914 |
| Male | 290 | 255 | 246 | 269 | 122 | 1182 |
Showing the first 100 of 140 sites across 3 countries. Choose a country and city above to see the rest.
The record gives a start of May 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2017, 2 years 1 month after primary completion. A results delay was requested in Jul 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →